Skip to main content
Premium Trial:

Request an Annual Quote

InSilixa Awarded NIH Grant to Develop Point-of-Care Test for Drug-resistant Tuberculosis

NEW YORK (GenomeWeb) – InSilixa announced yesterday that it has received a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health to develop a point-of-care molecular diagnostic test for the rapid detection and profiling of antibiotic-resistant Mycobacterium tuberculosis.

The test will be based on InSilixa's proprietary complementary metal-oxide semiconductor (CMOS) biochip technology, which is designed to detect pathogens in clinical samples and simultaneously identify their drug-resistance profiles using highly multiplexed targeted DNA sequencing.

According to the company, the test will check hundreds of known tuberculosis mutations and perform a comprehensive multi-drug resistance test for up to five key antibiotics in less than an hour.

InSilixa is also developing the CMOS biochips for the detection of other multi-drug resistant bacteria and for the detection, quantification, and characterization of HIV in blood samples.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.